trending Market Intelligence /marketintelligence/en/news-insights/trending/-hg4FobDEwGHs4ufpI7zFA2 content esgSubNav
In This List

Teva CEO rejects Israeli prime minister's appeal to keep Jerusalem plant running

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Teva CEO rejects Israeli prime minister's appeal to keep Jerusalem plant running

Teva Pharmaceutical Industries Ltd. CEO Kare Schultz rejected Israeli Prime Minister Benjamin Netanyahu's request to keep the company's manufacturing plant in Jerusalem open, Bloomberg News reported, citing a company statement.

Schultz said the measures are "painful, but absolutely vital."

The company plans on closing the manufacturing site by the end of 2019. The plant employs roughly 800 people, according to Bloomberg.

The generic drugmaker recently announced plans to slash a quarter of its workforce and suspend its dividend to cut its cost base by $3 billion in two years.

"Unfortunately, Teva is unable to consent to the request of the prime minister and ministers and avoid the closure of the plant in Jerusalem and the company will continue in the phased closure of the plant by the end of 2019," Reuters reported, citing Schultz.

Without "drastic" measures, Teva will be "increasingly vulnerable to potential takeover," Schultz said after a meeting with Netanyahu and the ministers of finance, economy and labor.